Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention and treatment of pyrotinib-associated diarrhea
ChiCTR2000032236Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of loperamide, pyrotinib, bifidobacterium infantis CGMCC0460.1 + lactobacillus acidophilus CGMCC0460.2 + enterococcus faecalis CGMCC0460.3 + bacillus cereus CGMCC0460.4 and diosmectite in diarrhea (5 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Stool frequency and Recovery time of grade 1-2 pyrotinib-associated diarrhea. Planned start May 2020; status: not yet recruiting.
02
Drugs
loperamidepyrotinibbifidobacterium infantis CGMCC0460.1 + lactobacillus acidophilus CGMCC0460.2 + enterococcus faecalis CGMCC0460.3 + bacillus cereus CGMCC0460.4diosmectite
03
Conditions
diarrhea
Beyond the preview
Go deeper on ChiCTR2000032236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032236.